Introduction
In the United States (US), children with end-stage heart failure listed for heart transplantation (HT) face the highest wait-list mortality in transplant medicine 1, 2 . While many factors may contribute, the lack of reliable miniaturized ventricular assist devices (VAD) designed specifically to support infants and children with terminal heart failure who fail medical therapy is often cited as the most important reason. Unlike adults and adolescents who have access to a wide variety of reliable FDA-approved long-term VADs, children have had none.
Thus, for years, pediatric clinicians have resorted to using short-term devices like extracorporeal membrane oxygenation (ECMO) to bridge children to heart transplant despite its dismal success rate 3 .
In recent years, the Berlin Heart EXCOR Pediatric VAD has emerged as an alternative to ECMO for bridging US children to transplant 4-6 . Recent data from the Investigational Device Exemption (IDE) trial of the EXCOR suggest that 88-92% of children can be bridged to transplant or recovery with a risk of neurological dysfunction of 29% 7 . However, published results from this trial of 48 subjects did not capture the experience of more than 75% of all US children implanted with the EXCOR because they met one or more exclusion criteria, such as complex heart disease (e.g. single-ventricle lesions), significant end-organ dysfunction at implant, or surgical implantation at one of 27 centers not officially participating in the trial (see online supplement for detailed list of IDE trial selection criteria). Analysis of this larger compassionate-use cohort-in combination with the original IDE trial subjects-provides a unique opportunity (1) to describe broader trends in EXCOR utilization in the United States, (2) to characterize the EXCOR 's performance in an unselected cohort of children (reflecting the so-called 'real-world' experience with the device), and (3) to identify risk factors for mortality ate 3 .
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Patients and Methods

Study Population and Data Source
All US children who received the Berlin Heart EXCOR Pediatric VAD between May 9, 2007 and December 31, 2010 and included in the sponsor's US regulatory database were identified using Berlin Heart's regulatory database. The EXCOR is a pneumatically-driven paracorporeal blood pump manufactured in 5 sizes (10, 25, 30, 50 , and 60 cc pump) and is capable of providing both left (LVAD) and biventricular (BVAD) assist device support 5 . The trial design, inclusion criteria and endpoints have been reported previously 5 . The IDE study was conducted at 17 centers in the US and Canada. Compassionate-use access to the EXCOR was available to transplant-eligible children who did not meet clinical inclusion criteria of the trial, or who were implanted at one of the 27 non-IDE study sites. Data was gathered by study coordinators at each site using a data platform adapted from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database 8 . An independent clinical events committee adjudicated the causes of death and adverse events for patients at the 17 IDE study sites but not non-study sites. An independent data and safety monitoring board monitored the study and reviewed outcome data. The study protocol was approved by each center's institutional review board and written informed consent was obtained for all patients.
Primary endpoint and study definitions
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Because an assumption of the model is that within each hazard phase there must be a linear relation between a continuous variable and the logarithm of the hazard ratio, each continuous variable was stratified by quintiles and plotted against the logarithm of the number of events divided by sum of follow-up time within each phase. If not linear, this suggested a family of transformations such as logarithmic and inverse on the one hand and squared or exponential on the other. These were generally scaled to the approximate mean of the variable to avoid arithmetic problems. The family of transformations was included in bootstrap variable selection.
In the aggregation phase of bagging, we clustered these transformations of scale (including untransformed) and selected the representative most frequently occurring (exploring also whether more than one was frequently observed, suggesting a quadratic-type relationship). After main effects were identified by bagging, interactions suggested by investigators were formed, including those among pump size, congenital diagnosis, BIVAD support, and IDE study center.
Using a fixed multivariable main effects model, these interactions were bagged in identical fashion as had been done for main effects. Sporadic missing values for variables (<10%) were filled by 5-fold multiple imputation 15 Table 1 . Overall, compassionate use patients were more likely to be younger, smaller, have CHD, be supported on ECMO, have worse end-organ function, and receive the smallest 10 milliliter pump.
Patient Survival
Survival at 12 months on EXCOR support was 75%, including 64% who survived to transplant, 6% who recovered (device explanted and patient survived 30 days), and 5% alive with the device in place, while mortality on support was 25% ( Figure 1A) . Compared to IDE subjects, children implanted under compassionate use were less likely to reach transplant (53% versus 85%) and were more likely to die (34% versus 7%, P<0.01) (Figure 1) . Table 2 summarizes the univariate predictors of death on EXCOR support.
Early mortality on EXCOR support was independently associated with lower body weight (Supplement Figure 2) , higher bilirubin (Supplement Figure 3) , and BIVAD support ( Table 3) . Late mortality was associated with bilirubin extremes (Supplement Figure 3) , and a clinical exclusion criteria at an IDE center. Baseline characteristics of the study y c coh oh o or or ort t t ar ar are e e ummarized in LVAD versus BIVAD support, cardiac diagnosis, pump size, IDE center status, and center volume were evaluated and were either non-significant or found not to improve model performance.
Adverse Events and Cause of death
The leading cause of death for the 51 patients who died on EXCOR support was a neurological insult, which occurred in 17 (33%) patients who died (Table 4) . Thromboembolic strokes causing death outnumbered hemorrhagic strokes by more than two to one. Respiratory failure, bleeding, and multi-system organ failure were the next most common causes. One patient death, at a non-IDE site, was adjudicated as a device malfunction (inadvertent cannula extraction while playing). Table 5 summarizes the overall frequency of adverse events in the IDE and compassionate-use cohorts, which were similar. Of those with stroke severity data available (primary IDE cohort), 13% (N=6) were categorized as severe or fatal, 4% (N=2) as moderate, and 13% (N=6) as mild or no deficit. 
Discussion
In this study, we found that among all 204 children supported with the Berlin Heart EXCOR Pediatric VAD in the US during the current era, 75% survived to heart transplant or recovery.
Twenty-five percent of children died, however the risk of death was not uniform for all children but varied significantly according to patient characteristics at EXCOR implant. Smaller patient size, decreased renal function, total bilirubin, and biventricular support were associated with death on EXCOR support whereas ECMO at implant and CHD were not. Neurological dysfunction occurred in 29% of children and was the leading cause of death.
Previous studies have reported widely divergent estimates of the EXCOR's benefit and safety profile, with mortality ranging from 0 to 45% and stroke ranging from 11% to 45% 5, 6, 17-23 . The wide variability in risk estimates stems from limitations of earlier studies including small sample size 18, 19, 22, 24 , or single-institution experiences 6, 24, 25 , which has made it difficult for clinicians to know precisely when to offer EXCOR support to their patients, or to provide families with contemporary risk-benefit data. Prior studies have also generally lacked objective clinical criteria for VAD implantation 6, 25 , or a standardized device treatment protocol 6, 25 -with uniform adverse event definitions, anticoagulation guidelines, and algorithm for pursuing BIVAD support-thus precluding the ability to know whether adverse events are related to the device itself or differences in patient management. Moreover, studies have tended to pool bridgeto-transplant and bridge-to-recovery patients 6, 25 , making it difficult to interpret transplant success rates. By contrast, the present report, which includes over 200 US children, represents by far the largest cohort of children supported with the EXCOR to date, is limited to children dysfunction occurred in 29% of children and was the leading cause of death.
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(2) that smaller patient weight is an independent risk factor for mortality, (3) the risk of neurological events (29%) is relatively constant across diverse patient groups, and (4) the strong univariate association between center volume and the risk of mortality (Figure 3) .
The single most important predictor of patient mortality on EXCOR support was the degree of end-organ dysfunction-specifically renal and hepatic dysfunction-at the time of VAD implant. Previous pediatric VAD studies have found no clear association between renal function and mortality, in part because of how renal function was analyzed in previous models (i.e. where the serum creatinine or creatinine clearance without adjustment for pediatric age were used) 5, 6 . By using GFR categories adjusted for age 9 , renal function was found not only to be statistically significant, but the single strongest term in the model. The mortality hazard related to total bilirubin was less pronounced but more intricate, conferring risk at both low and high bilirubin values (Table 3) . Further research is needed to understand the relationship between bilirubin and mortality.
Smaller infants were at higher risk of mortality where in this series nearly two-thirds of infants <5 kg died. It is unclear why smaller infants face a higher risk of death but may be BIVAD support was also associated with mortality, a consistent risk factor for death in the adult VAD experience 26, 27 and the report by Morales 5 . Whether the risks associated with BIVAD use are attributable to the devices themselves, or that patients implanted with BIVADs tend to be sicker as demonstrated in adults 26 (perhaps because of delayed device implant) or both is unclear. Programs have documented that as experience grows and patient selection matures, BIVAD use tends to decrease and that this is associated with a decrease in mortality.
Death occurred more frequently in children with CHD, on ECMO pre-implant, at non-IDE centers, and at centers with a lower EXCOR patient volume, but these differences were not statistically significant after adjusting for other factors. While children with CHD and those requiring ECMO remain readily identifiable risk groups, our findings suggest that their higher mortality is driven primarily by differences in patient size, end-organ dysfunction and use of BIVAD support, rather than either CHD or ECMO per se. Indeed, while our data suggest that ECMO should be generally viewed to increase the risk of VAD support in most children, it is possible that ECMO, when used strictly for short-term resuscitative support to normalize endorgan function immediately prior to VAD implant, may improve VAD candidacy in selected patients. This duality of effect for ECMO on mortality may account for its absence in the final multivariable model." Similarly, and perhaps more noteworthy for its absence in the model, is end to be sicker as demonstrated in adults 26 the strong univariable effect of center EXCOR volume on patient mortality (Figure 3) . Its absence suggests that the sharply lower patient mortality observed at centers implanting more devices may be best explained by experienced centers learning to implant the device in less sick patients over time, rather than other factors.
Neurological dysfunction, which occurred in 29% of EXCOR recipients, was the leading cause of death. While the observed risk in the present study is higher than the prevalence reported for adult continuous flow LVADs 28 , EXCOR recipients were considerably sicker than adult patients in these series. Moreover, the magnitude of the risk in EXCOR recipients is not appreciably different from first-generation adult pulsatile pumps used in the 1990s 29, 30 . Nevertheless, because of this and other factors, selected pediatric centers are expressing some preference to use adult continuous-flow VADs in their larger pediatric patients who may be eligible for both devices. However it is important to note that pediatric-specific adverse event data for adult continuous-flow devices are still relatively limited." Interestingly, most strokes in the present study were thromboembolic, rather than hemorrhagic, which may carry implications for refining further the anticoagulation balance point in future iterations of the anti-thrombotic protocol.
The findings of this study have several implications. First, our findings suggest that, for the very first time in the US, ventricular assist device therapy has emerged as a new standard of care for bridging children to transplant when optimal medical therapy failed. The relatively rapid adoption of this technology by more than 45 centers in the US and Canada-in a relatively short timeframe-likely stems from widespread appreciation of the unacceptably high waiting list mortality in US infants and children with or without ECMO 1, 31, 32 , the lack of alternative devices, the favorable German EXCOR experience 6, 25 , and a foundational shift in the While including a compassionate-use registry in the study design is costly, it provided a valuable mechanism to capture device performance data on subjects who fail to meet rigid inclusion criteria, which tends to happen frequently in pediatrics because of the heterogeneity of the patient population. 42 Lastly, and perhaps most importantly, our findings suggest that the single most effective way for centers to improve patient outcomes on EXCOR support is to devote careful attention 0.019 GF GF FR R R ca cate t go ori ri ie e es (ag age e ad adju ust sted ed) ) <3 30 30% pred dic icte ted d d 11 11 ( (5. 5 4% 4% 4%) ) 0 0 0 (0 (0 (0.0 .0% %) %) 1 11 1 1 (8 (8 (8 
Number of EXCOR Impalnts
Peri-Operative Myocardial Infarction
The clinical suspicion of myocardial infarction together with CK-MB or Troponin > 10 times the local hospital upper limits of normal, found within 7 days following VAD implant together with ECG findings consistent with acute myocardial infarction. (This definition uses the higher suggested limit for serum markers due to apical coring at the time of VAD placement, and does not use wall motion changes because the apical sewing ring inherently creates new wall motion abnormalities.)
Non-Perioperative Myocardial Infarction
The presence at > 7 days post-implant of two of the following three criteria: a) Chest pain which is characteristic of myocardial ischemia, b) ECG with a pattern or changes consistent with a myocardial infarction, and c) Troponin or CK (measured by standard clinical pathology/laboratory medicine methods) greater than the normal range for the local hospital with positive MB fraction (≥ 3% total CK). This should be accompanied by a new regional LV or RV wall motion abnormality on a myocardial imaging study.
Neurological Dysfunction
Any new, temporary or permanent, focal or global neurological deficit ascertained by a standard neurological examination (administered by a neurologist and documented with appropriate diagnostic tests and consultation note). The examining physician will distinguish between a transient ischemic attack (TIA), which is fully reversible within 24 hours (and without evidence of infarction), and a stroke, which lasts longer than 24 hours (or less than 24 hours if there is evidence of infarction). The neuromotor assessment must be readministered at 30 and 60 days following the event to document the presence and severity of neurological deficits. Each neurological event must be subcategorized as: 1) Transient Ischemic Attack (acute event that resolves completely within 24 hours with no evidence of infarction) 2) Ischemic or Hemorrhagic Cerebrovascular Accident/CVA (event that persists beyond 24 hours or less than 24 hours associated with infarction on an imaging study.
In addition, to above, for subjects < 6 months of age, any of the following: 3) New abnormality of head ultrasound 4) EEG positive for seizure activity with or without clinical seizure
Psychiatric Episode
Disturbance in thinking, emotion or behavior that causes substantial impairment in functioning or marked subjective distress requiring intervention. Intervention is the addition of new psychiatric medication, hospitalization, or referral to a mental health professional for treatment. Suicide is included in this definition.
Renal Dysfunction
Two categories of renal dysfunction will be identified:
Acute Renal Dysfunction
Abnormal kidney function requiring dialysis (including hemofiltration) in subjects who did not require this procedure prior to implant, or a rise in serum creatinine of
SUPPLEMENTAL TABLE 2 -Adverse event definitions used in the trial (adapted from INTERMACS)
Adverse Event Definition greater than 3 times baseline or greater than 5 mg/dL (in children, creatinine greater than 3 times upper limit of normal for age) sustained for over 48 hours.
Chronic Renal Dysfunction
An increase in serum creatinine of 2 mg/dl or greater above baseline, or requirement for hemodialysis sustained for at least 90 days.
Respiratory Failure
Impairment of respiratory function requiring reintubation, tracheostomy or (for subjects older than age 5 years) the inability to discontinue ventilatory support within six days (144 hours) post-VAD implant. This excludes intubation for re-operation or temporary intubation for diagnostic or therapeutic procedures.
Right Heart Failure
Symptoms and signs of persistent right ventricular dysfunction [central venous pressure (CVP) > 18 mmHg with a cardiac index <2.0 L/min/m 2 in the absence of elevated left atrial/pulmonary capillary wedge pressure (greater than 18 mmHg), tamponade, ventricular arrhythmias or pneumothorax] requiring either RVAD implantation or inotropic therapy; or requiring inhaled nitric oxide or inotropic therapy for a duration of more than 1 week at any time after LVAD implantation.
Arterial Non-CNS Thromboembolism
An acute systemic arterial perfusion deficit in any non-cerebrovascular organ system due to thromboembolism confirmed by one or more of the following: 1) Standard clinical and laboratory testing 2) Operative findings 3) Autopsy findings This definition excludes neurological events.
Venous Thromboembolism Event
Evidence of venous thromboembolic event (e.g. deep vein thrombosis, pulmonary embolism) by standard clinical and laboratory testing.
Wound Dehiscence
Disruption of the apposed surfaces of a surgical incision, excluding infectious etiology, and requiring surgical repair.
Other
An event that causes clinically relevant changes in the subject's health (e.g. cancer).
SUPPLEMENTAL FIGURE 1:
Death while supported on EXCOR.
C. Survival curve, enclosed by a confidence band equivalent to one standard error. Superimposed are non-parametric Kaplan-Meier estimates with a circle at each death and confidence bars also equivalent to one standard error. Number of patients remaining at risk is shown below figure.
SUPPLEMENTAL FIGURE 2:
Relationship of survival on EXCOR support to patient weight at implant. This is a nomogram of multivariable equation in Table 3 using the following assumptions: LVAD  implant, GFR normal 
